Emerging miRNA biomarkers in breast cancer: The role of miR-223, miR-326, and miR-429 in tumor profiling.

OBJECTIVE

Globally, breast cancer (BC) continues to be the primary cause of cancer-related death for women, underscoring the need for reliable biomarkers for early detection and improved patient outcomes. Because of their stability in biological fluids and their functions in controlling gene expression, microRNAs (miRNAs) have become attractive diagnostic tools.

MATERIALS AND

METHODS

With the hope of identifying new diagnostic biomarkers, this study attempted to study miR-223, miR-326, and miR-429 expression patterns in BC patients. Here, we used quantitative real-time PCR (qRT-PCR) to examine the miRNA expression levels in serum samples taken from 64 BC patients and 64 healthy controls.

RESULTS

In comparison to controls, BC patients showed a substantial decrease in miR-223 and miR-326 and an increase in miR-429 (p < 0.05). With an AUC of 0.88, sensitivity of 76%, and specificity of 78%, miR-326 showed the best diagnostic accuracy according to the Receiver Operating Characteristic (ROC) curve analysis. Although there was no obvious connection between miRNA expression and clinical characteristics like tumor size, lymph node metastases, or TNM stage, a notable association was observed between miRNA expression and body mass index (BMI), with higher expression levels in obese patients (p < 0.05).

CONCLUSION

According to these findings, miR-223, miR-326, and miR-429, particularly miR-326, hold promise as diagnostic biomarkers for BC. Further studies with larger cohorts and functional validation are warranted to confirm their diagnostic utility and explore their roles in BC pathogenesis.